SynthesisWorld journal of surgical oncology2024
Pan-immune-inflammation value as a novel prognostic biomarker for digestive system cancers: a meta-analysis.
Synthesis in World journal of surgical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Prognostic value of the pretreatment pan-immune-inflammation value in patients with head and neck squamous cell carcinoma: a systematic review and meta-analysis.Frontiers in oncology · 2026Pooled it
- Pooled it
- Prognostic significance of the pretreatment pan-immune-inflammation value in colorectal cancer patients: an updated meta-analysis.Frontiers in oncology · 2025Pooled it
- Dynamic Assessment of Systemic Inflammatory Markers in Predicting Pathological Complete Response After Neoadjuvant Treatment in Triple-Negative Breast Cancer.Journal of clinical medicine · 2026Article
- Association between pan-immune-inflammation value and prognosis in lung cancer patients: a systematic review and meta-analysis.Translational cancer research · 2026Article
- Article
- Pretreatment Pan-Immune-Inflammation Value and Corrected Prognostic Nutritional Index for 24-Month Recurrence Risk Stratification After Neoadjuvant Chemotherapy and Surgery in Stage III Endometrial Cancer.International journal of women's health · 2026Article
- Diagnostic value of cellular inflammatory markers in CNS tumor patients undergoing glucocorticoid therapy.Frontiers in oncology · 2026Article
- Predictive utility of systemic inflammatory response index and pan-immune-inflammatory value in assessing myocardial infarction risk among cases with unstable angina.Scientific reports · 2025Article
- Lymph Node Ratio as a Risk Factor for Early Recurrence in Older Patients with Stage II/III Gastric Cancer: A Retrospective Study.Journal of clinical medicine · 2025Article
- A Promising Prognostic Indicator for Pleural Mesothelioma: Pan-Immuno-Inflammation Value.Journal of clinical medicine · 2025Article
- Pan-immune-inflammation value and mortality in the US adult MASLD: a nonlinear NHANES analysis.BMC gastroenterology · 2025Article
- Construction of a Nomogram Model for Predicting Pathologic Complete Response in Breast Cancer Neoadjuvant Chemotherapy Based on the Pan-Immune Inflammation Value.Current oncology (Toronto, Ont.) · 2025Observational
- Are the systemic immune-inflammation index and panimmune-inflammation value predictive indicators for the decision of operative treatment in adhesive small bowel obstruction?Ulusal travma ve acil cerrahi dergisi = Turkish journal of trauma & emergency surgery : TJTES · 2025Article
- Joint association between pan-immune inflammation value and physical pain with self-perception of patients in rheumatoid arthritis: a retrospective cohort study employing traditional statistics and interpretable machine learning.Frontiers in immunology · 2025Article
- Pan-immune-inflammation value as an independent prognostic marker in patients with brain metastases.Frontiers in oncology · 2025Article
- The association of the pan-immune-inflammation value with mortality in patients monitored in the intensive care unit after cardiopulmonary resuscitation.Frontiers in medicine · 2025Article
- Comprehensive analysis of Pan-Immune Inflammation and all-cause mortality in rheumatoid arthritis: a database-driven approach, 1999-2018.Frontiers in immunology · 2025Article
- Gender differences in the association between pan-immune-inflammation value and probable depression: A cross-sectional study.PloS one · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundDigestive system cancers pose a significant global health challenge with high incidence and mortality rates. Inflammation is a key factor in cancer progression, necessitating reliable prognostic indicators. The pan-immune-inflammation value (PIV), as a new biomarker of immune-inflammatory response, has emerged as a potential prognostic biomarker for cancers.
methodsWe performed a meta-analysis to evaluate the prognostic significance of PIV in digestive system cancers. Our search, up to June 2024, included 20 studies from 19 articles with 5037 patients. We extracted and analyzed data on PIV levels and assessed hazard ratios (HRs) for overall survival (OS), progression-free survival (PFS), disease-free survival (DFS), recurrence-free survival (RFS), and cancer-specific survival (CSS) using STATA 14.0.
resultsOur analysis found that high PIV levels were significantly associated with poor prognosis in patients with digestive system cancers. Specifically, high PIV was linked to shorter OS (HR = 2.039, P < 0.001), PFS (HR = 1.877, P = 0.028), DFS (HR = 1.624, P = 0.005), RFS (HR = 2.393, P = 0.037), and CSS (HR = 2.053, P < 0.001). Additionally, the adverse prognostic impact of high PIV on OS was consistent across different cancer types, including digestive tract, colorectal, esophageal, and hepatobiliary pancreatic cancers. Although some heterogeneity was observed, sensitivity and bias analyses confirmed the reliability of these findings.
conclusionsPIV was a valuable and practical prognostic marker for digestive system cancers, providing significant predictive value across multiple survival metrics. Its simplicity and minimal invasiveness nature support its potential integration into routine clinical practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.